<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00650663</url>
  </required_header>
  <id_info>
    <org_study_id>P03377</org_study_id>
    <nct_id>NCT00650663</nct_id>
  </id_info>
  <brief_title>Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subjects With Primary Hypercholesterolemia (P03377)</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized Study to Evaluate the Lipid-Altering Efficacy, Safety, and Tolerability of Ezetimibe Coadministered With Simvastatin Versus Simvastatin Monotherapy in African-American Subjects With Primary Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether coadministration of ezetimibe 10 mg/day with
      simvastatin 20 mg/day for 12 weeks will result in greater reduction of LDL-C, total
      cholesterol (TC), triglycerides (TG), non HDL-C, and apolipoprotein B (ApoB), and greater
      increase in HDL-C, compared with simvastatin 20 mg/day as monotherapy for 12 weeks in
      African-American subjects with primary hypercholesterolemia. This study is being performed to
      better define the efficacy of ezetimibe coadministered with simvastatin in this population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2003</start_date>
  <completion_date type="Actual">September 1, 2004</completion_date>
  <primary_completion_date type="Actual">September 1, 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in LDL-C from baseline to endpoint.</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to endpoint in TC, TG, HDL-C, non-HDL-C, and ApoB.</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">247</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Ezetimibe + Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe + Simvastatin</intervention_name>
    <description>oral tablets; ezetimibe 10 mg and simvastatin 20 mg once daily for 12 weeks</description>
    <arm_group_label>Ezetimibe + Simvastatin</arm_group_label>
    <other_name>SCH 58235</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>oral tablet; simvastatin 20 mg once daily for 12 weeks</description>
    <arm_group_label>Simvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult African-American or Black subjects with diagnosis of primary
             hypercholesterolemia with plasma LDL-C &gt;=145 mg/dL and &lt;=250 mg/dL, and plasma TG
             &lt;=350 mg/dL

          -  Postmenopausal women who are receiving postmenopausal hormonal therapy or raloxifene
             must be maintained on a stable HRT or raloxifene regimen for at least 6 weeks and
             throughout the study

          -  Female subjects of non-childbearing potential

          -  Willingness to give written consent, participate and complete all study-related
             procedures, and ability to follow a stable NCEP Step I (or stricter) diet regimen and
             keep a diet diary when required.

          -  Clinical laboratory tests (CBC, blood chemistries, and urinalysis) within normal
             limits (except as noted below) or clinically acceptable.

          -  ALT (SGPT) and AST (SGOT) concentrations &lt;=2 times the upper limit of normal (ULN) and
             creatine phosphokinase &lt;=2 times the ULN.

        Exclusion Criteria:

          -  Pregnancy or any other situation, condition, or illness that, in the opinion of the
             investigator, may interfere with optimal participation in the study

          -  Secondary forms of hyperlipidemia or underlying disease likely to limit life span to
             less than one year

          -  Known hypersensitivity or any contraindication to simvastatin or ezetimibe

          -  Use of investigational drugs within 30 days of study entry

          -  Concomitant illnesses: congestive heart failure NYHA Class III or IV; obstructive
             cardiomyopathy; uncontrolled cardiac arrhythmias; severe aortic stenosis; MI, CABG or
             angioplasty within 3 months of study; unstable or severe peripheral artery disease;
             unstable angina pectoris; study-limiting disorders of the hematologic, digestive or
             central nervous systems including cerebrovascular disease and degenerative disease;
             uncontrolled or newly diagnosed diabetes mellitus; uncontrolled endocrine or metabolic
             disease known to influence serum lipids or lipoproteins (clinically euthyroid subjects
             on stable replacement doses of thyroid hormone are eligible for enrollment);
             uncontrolled hypertension; known impairment of renal function (plasma creatinine &gt;2.0
             mg/dL), dysproteinemia, nephrotic syndrome or other renal disease (24-hour urinary
             protein 3+ or 1 gram); hepatobiliary or hepatic disease (AST or ALT &gt;2 times the upper
             limit of the reference range); HIV positive; known coagulopathy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Rodney RA, Sugimoto D, Wagman B, Zieve F, Kerzner B, Strony J, Yang B, Suresh R, Veltri E. Efficacy and safety of coadministration of ezetimibe and simvastatin in African-American patients with primary hypercholesterolemia. J Natl Med Assoc. 2006 May;98(5):772-8.</citation>
    <PMID>16749654</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2008</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

